RU2014132888A - Стабильные и растворимые антитела, ингибирующие vegf - Google Patents
Стабильные и растворимые антитела, ингибирующие vegf Download PDFInfo
- Publication number
- RU2014132888A RU2014132888A RU2014132888/10A RU2014132888A RU2014132888A RU 2014132888 A RU2014132888 A RU 2014132888A RU 2014132888/10 A RU2014132888/10 A RU 2014132888/10A RU 2014132888 A RU2014132888 A RU 2014132888A RU 2014132888 A RU2014132888 A RU 2014132888A
- Authority
- RU
- Russia
- Prior art keywords
- carcinoma
- seq
- variable region
- vegf
- binding fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
1. Рекомбинантное антитело, содержащее вариабельную область тяжелой цепи (VH), где VH содержит СDRH1, СDRH2 и СDRH3 последовательности SEQ ID NO:8, SEQ ID NO:20 и SEQ ID NO:32 соответственно и вариабельную область легкой цепи (VL), где VL содержит СDRL1, СDRL2 и СDRL3 последовательности SEQ ID NO:43, SEQ ID NO:55 и SEQ ID NO:66 соответственно.2. Рекомбинантное антитело по п. 1, где вариабельная область тяжелой цепи содержит аминокислотную последовательность SEQ ID NO:164 и вариабельная область легкой цепи содержит аминокислотную последовательность SEQ ID NO:87.3. Антиген-связывающий фрагмент рекомбинантного антитела по п. 1 или 2, где фрагмент представляет собой scFv или Fab, F(ab')или Fab'.4. Антиген-связывающий фрагмент по п. 3, где фрагмент представляет собой scFv и где вариабельная область тяжелой цепи и вариабельная область легкой цепи связаны последовательностью SEQ ID NO:181.5. Фармацевтическая композиция, содержащая рекомбинантное антитело по п. 1 или 2.6. Фармацевтическая композиция, содержащая антиген-связывающий фрагмент по п. 3.7. Фармацевтическая композиция, содержащая антиген-связывающий фрагмент по п. 4.8. Способ лечения VEGF-опосредованного заболевания у человека, включающий введение индивидууму терапевтически эффективного количества антитела по п. 1 или 2, обеспечивая таким образом, лечение VEGF-опосредованного заболевания.9. Способ по п. 8, где VEGF-опосредованное заболевание выбрано из группы, состоящей из возрастной дегенерации желтого пятна, неоваскулярной глаукомы, диабетической ретинопатии, ретинопатии недоношенных, ретролентальной фиброплазии, карцином молочной железы, карцином легких, желудочных карцином, эзофагеальных карцином, колоректальных карцином, карцином печени, ка�
Claims (13)
1. Рекомбинантное антитело, содержащее вариабельную область тяжелой цепи (VH), где VH содержит СDRH1, СDRH2 и СDRH3 последовательности SEQ ID NO:8, SEQ ID NO:20 и SEQ ID NO:32 соответственно и вариабельную область легкой цепи (VL), где VL содержит СDRL1, СDRL2 и СDRL3 последовательности SEQ ID NO:43, SEQ ID NO:55 и SEQ ID NO:66 соответственно.
2. Рекомбинантное антитело по п. 1, где вариабельная область тяжелой цепи содержит аминокислотную последовательность SEQ ID NO:164 и вариабельная область легкой цепи содержит аминокислотную последовательность SEQ ID NO:87.
3. Антиген-связывающий фрагмент рекомбинантного антитела по п. 1 или 2, где фрагмент представляет собой scFv или Fab, F(ab')2 или Fab'.
4. Антиген-связывающий фрагмент по п. 3, где фрагмент представляет собой scFv и где вариабельная область тяжелой цепи и вариабельная область легкой цепи связаны последовательностью SEQ ID NO:181.
5. Фармацевтическая композиция, содержащая рекомбинантное антитело по п. 1 или 2.
6. Фармацевтическая композиция, содержащая антиген-связывающий фрагмент по п. 3.
7. Фармацевтическая композиция, содержащая антиген-связывающий фрагмент по п. 4.
8. Способ лечения VEGF-опосредованного заболевания у человека, включающий введение индивидууму терапевтически эффективного количества антитела по п. 1 или 2, обеспечивая таким образом, лечение VEGF-опосредованного заболевания.
9. Способ по п. 8, где VEGF-опосредованное заболевание выбрано из группы, состоящей из возрастной дегенерации желтого пятна, неоваскулярной глаукомы, диабетической ретинопатии, ретинопатии недоношенных, ретролентальной фиброплазии, карцином молочной железы, карцином легких, желудочных карцином, эзофагеальных карцином, колоректальных карцином, карцином печени, карцином яичника, ком, арренобластом, карцином шейки матки, эндометриальной карциномы, эндометриальной гиперплазии, эндометриоза, фибросарком, хориокарциномы, рака головы и шеи, назофарингеальной карциномы, карцином гортани, гепатобластомы, саркомы Капоши, меланомы, кожных карцином, гемангиомы, кавернозной гемангиомы, гемангиобластомы, карцином поджелудочной железы, ретинобластомы, астроцитомы, глиобластомы, Шванномы, олигодендроглиомы, медуллобластомы, нейробластом, рабдомиосаркомы, остеогенной саркомы, лейомиосарком, карцином мочеполовых путей, карцином щитовидной железы, опухоли Вильмса, почечно-клеточной карциномы, рака предстательной железы, аномальной пролиферации сосудов, ассоциированной с факоматозом, эдемы (например, ассоциированной с опухолями головного мозга), синдрома Мейжа, ревматоидного артрита, псориаза и атеросклероза.
10. Способ лечения VEGF-опосредованного заболевания у человека, включающий введение индивидууму терапевтически эффективного количества антиген-связывающего фрагмента по п. 3, обеспечивая, таким образом, лечение VEGF-опосредованного заболевания.
11. Способ по п. 10, где VEGF-опосредованное заболевание
выбрано из группы, состоящей из возрастной дегенерации желтого пятна, неоваскулярной глаукомы, диабетической ретинопатии, ретинопатии недоношенных, ретролентальной фиброплазии, карцином молочной железы, карцином легких, желудочных карцином, эзофагеальных карцином, колоректальных карцином, карцином печени, карцином яичника, ком, арренобластом, карцином шейки матки, эндометриальной карциномы, эндометриальной гиперплазии, эндометриоза, фибросарком, хориокарциномы, рака головы и шеи, назофарингеальной карциномы, карцином гортани, гепатобластомы, саркомы Капоши, меланомы, кожных карцином, гемангиомы, кавернозной гемангиомы, гемангиобластомы, карцином поджелудочной железы, ретинобластомы, астроцитомы, глиобластомы, Шванномы, олигодендроглиомы, медуллобластомы, нейробластом, рабдомиосаркомы, остеогенной саркомы, лейомиосарком, карцином мочеполовых путей, карцином щитовидной железы, опухоли Вильмса, почечно-клеточной карциномы, рака предстательной железы, аномальной пролиферации сосудов, ассоциированной с факоматозом, эдемы (например, ассоциированной с опухолями головного мозга), синдрома Мейжа, ревматоидного артрита, псориаза и атеросклероза.
12. Биспецифическая молекула, содержащая антитело по п. 1 или 2 или антиген-связывающий фрагмент по п. 3 или 4.
13. Биспецифическая молекула по п. 12, которая является мультиспецифичной.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7569208P | 2008-06-25 | 2008-06-25 | |
| US7569708P | 2008-06-25 | 2008-06-25 | |
| US13321208P | 2008-06-25 | 2008-06-25 | |
| US61/075,692 | 2008-06-25 | ||
| US61/075,697 | 2008-06-25 | ||
| US61/133,212 | 2008-06-25 | ||
| US15504109P | 2009-02-24 | 2009-02-24 | |
| US61/155,041 | 2009-02-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011102583A Division RU2531523C3 (ru) | 2008-06-25 | 2009-06-25 | Стабильные и растворимые антитела, ингибирующие vegf |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016119152A Division RU2648152C2 (ru) | 2008-06-25 | 2016-05-18 | Стабильные и растворимые антитела, ингибирующие vegf |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2014132888A true RU2014132888A (ru) | 2015-12-10 |
| RU2588467C2 RU2588467C2 (ru) | 2016-06-27 |
| RU2588467C3 RU2588467C3 (ru) | 2021-10-20 |
Family
ID=41209803
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011102583A RU2531523C3 (ru) | 2008-06-25 | 2009-06-25 | Стабильные и растворимые антитела, ингибирующие vegf |
| RU2014132888A RU2588467C3 (ru) | 2008-06-25 | 2009-06-25 | Стабильные и растворимые антитела, ингибирующие vegf |
| RU2013133802/10A RU2013133802A (ru) | 2008-06-25 | 2013-07-19 | Стабильные и растворимые антитела, ингибирующие vegf |
| RU2016119152A RU2648152C2 (ru) | 2008-06-25 | 2016-05-18 | Стабильные и растворимые антитела, ингибирующие vegf |
| RU2018105866A RU2696972C1 (ru) | 2008-06-25 | 2018-02-16 | Стабильные и растворимые антитела, ингибирующие vegf |
| RU2019120079A RU2747735C3 (ru) | 2008-06-25 | 2019-06-27 | Стабильные и растворимые антитела, ингибирующие vegf |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011102583A RU2531523C3 (ru) | 2008-06-25 | 2009-06-25 | Стабильные и растворимые антитела, ингибирующие vegf |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013133802/10A RU2013133802A (ru) | 2008-06-25 | 2013-07-19 | Стабильные и растворимые антитела, ингибирующие vegf |
| RU2016119152A RU2648152C2 (ru) | 2008-06-25 | 2016-05-18 | Стабильные и растворимые антитела, ингибирующие vegf |
| RU2018105866A RU2696972C1 (ru) | 2008-06-25 | 2018-02-16 | Стабильные и растворимые антитела, ингибирующие vegf |
| RU2019120079A RU2747735C3 (ru) | 2008-06-25 | 2019-06-27 | Стабильные и растворимые антитела, ингибирующие vegf |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US8349322B2 (ru) |
| EP (3) | EP3216803B1 (ru) |
| JP (7) | JP5956752B2 (ru) |
| KR (8) | KR20180005753A (ru) |
| CN (3) | CN104961828B (ru) |
| AU (1) | AU2009264565C1 (ru) |
| BR (1) | BRPI0914251B1 (ru) |
| CA (2) | CA2727839C (ru) |
| CL (1) | CL2010001544A1 (ru) |
| CY (3) | CY1118829T1 (ru) |
| DK (3) | DK3216803T3 (ru) |
| ES (3) | ES2793008T3 (ru) |
| FI (1) | FI3722310T3 (ru) |
| HR (3) | HRP20241467T1 (ru) |
| HU (4) | HUE068894T2 (ru) |
| LT (4) | LT3216803T (ru) |
| MX (3) | MX392435B (ru) |
| NL (1) | NL301058I2 (ru) |
| NO (1) | NO2020021I1 (ru) |
| PH (1) | PH12015501593A1 (ru) |
| PL (3) | PL3216803T3 (ru) |
| PT (3) | PT3722310T (ru) |
| RU (6) | RU2531523C3 (ru) |
| SI (3) | SI2307454T1 (ru) |
| WO (1) | WO2009155724A2 (ru) |
| ZA (1) | ZA201008594B (ru) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2648284C (en) | 2006-04-07 | 2016-08-16 | The Procter & Gamble Company | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
| KR20180005753A (ko) * | 2008-06-25 | 2018-01-16 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체 |
| TR201808591T4 (tr) | 2008-06-25 | 2018-07-23 | Esbatech Alcon Biomed Res Unit | Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması. |
| EP2307457B2 (en) | 2008-06-25 | 2022-06-22 | Novartis AG | Stable and soluble antibodies inhibiting tnf |
| US8637022B2 (en) | 2008-06-30 | 2014-01-28 | Esbatech, An Alcon Biomedical Research Unit Llc | Functionalized polypeptides |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| WO2010096941A1 (en) | 2009-02-24 | 2010-09-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods for identifying immunobinders of cell-surface antigens |
| EP2445923B1 (en) | 2009-06-22 | 2018-09-05 | Amgen, Inc | Refolding proteins using a chemically controlled redox state |
| EP3660032B1 (en) | 2009-06-25 | 2025-10-22 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
| ES2662100T3 (es) * | 2010-10-19 | 2018-04-05 | Mayo Foundation For Medical Education And Research | Anticuerpos humanos y diagnósticos y usos terapéuticos de los mismos para el tratamiento de la enfermedad neurológica |
| UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| PH12014500456A1 (en) * | 2011-09-16 | 2014-04-14 | Ucb Pharma Sa | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |
| CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
| WO2013113820A1 (en) | 2012-02-02 | 2013-08-08 | Esbatech - A Novartis Company Llc | Antibody-containing sustained-release formulation for ocular administration |
| DK3495387T3 (da) | 2012-07-13 | 2021-11-08 | Roche Glycart Ag | Bispecifikke anti-VEGF-/anti-ANG-2-antistoffer og deres anvendelse ved behandling af okulære vaskulære sygdomme |
| SG11201503566QA (en) | 2012-12-18 | 2015-09-29 | Novartis Ag | Compositions and methods that utilize a peptide tag that binds to hyaluronan |
| ES2771478T3 (es) | 2013-02-18 | 2020-07-06 | Vegenics Pty Ltd | Moléculas de unión a ligando y usos de las mismas |
| KR101541478B1 (ko) * | 2013-05-31 | 2015-08-05 | 동아쏘시오홀딩스 주식회사 | 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물 |
| SG10201811017QA (en) * | 2013-06-26 | 2019-01-30 | Numab Innovation Ag | Novel antibody frameworks |
| MX2016000364A (es) | 2013-07-12 | 2016-05-09 | Ophthotech Corp | Metodos para tratar o prevenir afecciones oftalmologicas. |
| WO2015076425A1 (ja) * | 2013-11-25 | 2015-05-28 | リンク・ジェノミクス株式会社 | 新規モノクローナル抗体 |
| EP3828202A1 (en) | 2014-05-12 | 2021-06-02 | Formycon AG | Pre-filled plastic syringe containing a vegf antagonist |
| US20170327553A1 (en) | 2014-06-25 | 2017-11-16 | Novartis Ag | Compositions and methods for long acting proteins |
| US20170290876A1 (en) | 2014-06-25 | 2017-10-12 | Novartis Ag | Compositions and methods for long acting proteins |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| KR102390359B1 (ko) | 2014-09-29 | 2022-04-22 | 삼성전자주식회사 | 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체 |
| TWI705827B (zh) * | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US10093730B2 (en) | 2014-11-10 | 2018-10-09 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| AU2016210918A1 (en) * | 2015-01-28 | 2017-07-13 | Pfizer Inc., | Stable aqueous anti- vascular endothelial growth factor (VEGF) antibody formulation |
| JP6924148B2 (ja) | 2015-04-16 | 2021-08-25 | ハー・ルンドベック・アクチエゼルスカベット | 抗ｐａｃａｐ抗体及びそれらの使用 |
| US10851399B2 (en) * | 2015-06-25 | 2020-12-01 | Native Microbials, Inc. | Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| CN107922975B (zh) | 2015-08-12 | 2022-06-28 | 诺华股份有限公司 | 治疗眼科病症的方法 |
| WO2017075212A1 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-htra1 antibodies and methods of use thereof |
| CN108350450B (zh) * | 2015-11-09 | 2022-07-05 | 国立大学法人京都工艺纤维大学 | 人血清来源的IgG多克隆抗体的分离剂、以及使用其的人血清来源的IgG多克隆抗体的分离方法 |
| US10925927B2 (en) | 2015-11-18 | 2021-02-23 | Formycon Ag | Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist |
| EP3377151A1 (en) | 2015-11-18 | 2018-09-26 | Formycon AG | Pre-filled plastic syringe containing a vegf antagonist |
| EP3377040B8 (en) | 2015-11-18 | 2024-06-05 | SiO2 Medical Products, Inc. | Pharmaceutical package for ophthalmic formulations |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| NZ783685A (en) | 2015-12-30 | 2025-09-26 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| US11007259B2 (en) | 2016-01-06 | 2021-05-18 | Order-Made Medical Research Inc. | High-affinity anti-VEGF antibody |
| US11008387B2 (en) | 2016-01-06 | 2021-05-18 | Order-Made Medical Research Inc. | Antibody inhibiting binding of VEGF to NRP1 |
| USD789171S1 (en) | 2016-01-21 | 2017-06-13 | Nomis Llc | Right angle drive |
| WO2017129685A1 (en) | 2016-01-26 | 2017-08-03 | Formycon Ag | Liquid formulation of a vegf antagonist |
| CN109562163B (zh) | 2016-02-05 | 2022-04-08 | 得克萨斯大学体系董事会 | Egfl6特异性单克隆抗体及其使用方法 |
| WO2017156423A2 (en) * | 2016-03-11 | 2017-09-14 | Integrated Biotherapeutics, Inc. | Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever |
| EP3222673A1 (de) * | 2016-03-23 | 2017-09-27 | LANXESS Deutschland GmbH | Metallazopigmente |
| KR20190005873A (ko) | 2016-04-15 | 2019-01-16 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 항-pacap 항체 및 그의 용도 |
| CA3028238C (en) | 2016-06-30 | 2024-01-02 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
| CN109890982B (zh) | 2016-07-08 | 2023-07-07 | 基因泰克公司 | 通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法 |
| JP7046089B2 (ja) * | 2017-03-09 | 2022-04-01 | マブ ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング | ヒトｉｌ－１ｒ７に特異的に結合する抗体 |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| KR102607655B1 (ko) | 2017-05-19 | 2023-11-28 | 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 | 리폴딩된 재조합 인간화 라니비주맙의 제조 방법 |
| US20200237997A1 (en) | 2017-05-24 | 2020-07-30 | Formycon Ag | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
| CA3063995A1 (en) | 2017-05-24 | 2018-11-29 | Sio2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
| WO2018215580A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Method for sterilizing prefilled plastic syringes containing a vegf antagonist |
| JP7474193B2 (ja) * | 2017-06-25 | 2024-04-24 | システィミューン， インク． | 多重特異性抗体とその作製及び使用方法 |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| KR20250052478A (ko) | 2017-11-27 | 2025-04-18 | 4디 몰레큘러 테라퓨틱스 아이엔씨. | 아데노-관련 바이러스 변이체 캡시드 및 혈관 신생을 억제하기 위한 용도 |
| EP3731865A1 (en) * | 2017-12-29 | 2020-11-04 | F. Hoffmann-La Roche AG | Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody |
| EP3740509A4 (en) | 2018-01-17 | 2022-06-22 | Apexigen, Inc. | Anti-pd-l1 antibodies and methods of use |
| SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
| MX2020009140A (es) | 2018-03-16 | 2020-09-28 | Novartis Ag | Metodos para el tratamiento de enfermedades oculares. |
| US20210163605A1 (en) * | 2018-04-06 | 2021-06-03 | Eli Lilly And Company | Ramucirumab for the treatment of cancers in pediatric patients |
| US11672826B2 (en) | 2018-08-30 | 2023-06-13 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| SG11202101780WA (en) | 2018-08-30 | 2021-03-30 | Hcw Biologics Inc | Single-chain chimeric polypeptides and uses thereof |
| JP7397874B2 (ja) | 2018-08-30 | 2023-12-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| CA3109366A1 (en) * | 2018-09-13 | 2020-03-19 | The Board Of Regents Of The University Of Texas System | Novel lilrb4 antibodies and uses thereof |
| JP7695187B2 (ja) | 2018-09-24 | 2025-06-18 | アイポイント ファーマシューティカルズ， インコーポレイテッド | ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体 |
| CA3119241A1 (en) | 2018-12-18 | 2020-06-25 | Novartis Ag | Protein solution formulation containing high concentration of an anti-vegf antibody |
| USD907455S1 (en) | 2019-05-21 | 2021-01-12 | Nomis Llc | Right angle drive attachment |
| USD907456S1 (en) | 2019-05-21 | 2021-01-12 | Nomis Llc | Right angle drill attachment |
| EP3987010A1 (en) | 2019-06-21 | 2022-04-27 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| WO2021048806A1 (en) | 2019-09-13 | 2021-03-18 | Novartis Ag | Methods for treating ocular diseases |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| EP4100443A4 (en) * | 2020-02-07 | 2024-05-15 | Agency for Science, Technology and Research | Antigen-binding molecules against alppl2 and/or alpp and uses thereof |
| US12115191B2 (en) | 2020-02-11 | 2024-10-15 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| KR20220140572A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 조절 t 세포를 활성화시키는 방법 |
| WO2021163299A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Chromatography resin and uses thereof |
| US20230340112A1 (en) * | 2020-02-28 | 2023-10-26 | Apexigen, Inc. | Anti-sirpa antibodies and methods of use |
| US20230340114A1 (en) * | 2020-03-12 | 2023-10-26 | Immune-Onc Therapeutics, Inc. | Novel anti-lilrb4 antibodies and derivative products |
| JP7767298B2 (ja) | 2020-03-13 | 2025-11-11 | ジェネンテック， インコーポレイテッド | 抗インターロイキン－３３抗体及びその使用 |
| EP4143231A1 (en) | 2020-04-29 | 2023-03-08 | HCW Biologics, Inc. | Anti-cd26 proteins and uses thereof |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| IL298608A (en) | 2020-06-01 | 2023-01-01 | Hcw Biologics Inc | Methods of treating aging-related disorders |
| PH12023550015A1 (en) * | 2020-07-16 | 2024-03-11 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
| CA3198668A1 (en) | 2020-10-15 | 2022-04-21 | Genentech, Inc. | Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics |
| TW202237181A (zh) | 2020-11-25 | 2022-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| WO2022201084A1 (en) | 2021-03-26 | 2022-09-29 | Novartis Ag | Methods for treating ocular diseases |
| US12472148B2 (en) | 2021-04-26 | 2025-11-18 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| EP4145456A1 (en) | 2021-09-06 | 2023-03-08 | Bayer AG | Prediction of a change related to a macular fluid |
| KR102809807B1 (ko) | 2021-12-21 | 2025-05-16 | 한림대학교 산학협력단 | 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법 |
| JP2025508939A (ja) | 2022-03-02 | 2025-04-10 | イミュニティーバイオ インコーポレイテッド | 膵臓癌の治療方法 |
| TW202337496A (zh) | 2022-03-17 | 2023-10-01 | 瑞士商諾華公司 | 治療新生血管性年齡相關性黃斑點退化之方法 |
| CN117820474A (zh) * | 2023-04-25 | 2024-04-05 | 南京贝思奥生物科技有限公司 | 改善眼部血管新生相关疾病的药物及其应用 |
| CN117069848B (zh) * | 2023-08-02 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人cd146兔单克隆抗体及其应用 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5147638A (en) | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| OA10149A (en) | 1991-03-29 | 1996-12-18 | Genentech Inc | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| ES2309119T3 (es) | 1992-10-28 | 2008-12-16 | Genentech, Inc. | Utilizacion de antagonistas del factor de crecimiento celular vegf. |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| DE69726003T2 (de) * | 1996-07-16 | 2004-08-26 | Andreas Plückthun | Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit |
| US6986890B1 (en) | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| PT1787999E (pt) * | 1997-04-07 | 2010-11-11 | Genentech Inc | Anticorpos anti-vegf |
| CN100480269C (zh) * | 1997-04-07 | 2009-04-22 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
| US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
| WO2000034337A1 (en) * | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
| AU3737500A (en) * | 1999-03-12 | 2000-09-28 | Genentech Inc. | Method of preventing the death of retinal neurons and treating ocular diseases |
| US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| EP1233790A2 (en) | 1999-10-22 | 2002-08-28 | Ludwig Institute For Cancer Research | A33 antigen specific immunoglobulin products in cancer therapy |
| DK1242457T3 (da) | 1999-12-28 | 2004-12-20 | Esbatech Ag | Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| DE10201450B4 (de) | 2002-01-16 | 2004-09-02 | Infineon Technologies Ag | Carry-Skip-Addierer für verschlüsselte Daten |
| US6576941B1 (en) | 2002-02-20 | 2003-06-10 | Samsung Electronics Co., Ltd. | Ferroelectric capacitors on protruding portions of conductive plugs having a smaller cross-sectional size than base portions thereof |
| CN1187373C (zh) * | 2002-03-20 | 2005-02-02 | 上海中信国健药业有限公司 | 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物 |
| KR100708398B1 (ko) | 2002-03-22 | 2007-04-18 | (주) 에이프로젠 | 인간화 항체 및 이의 제조방법 |
| PT1506236E (pt) | 2002-05-22 | 2013-03-27 | Esbatech A Novartis Co Llc | Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas |
| AU2003264009A1 (en) * | 2002-08-15 | 2004-03-03 | Epitomics, Inc. | Humanized rabbit antibodies |
| US20050186208A1 (en) | 2003-05-30 | 2005-08-25 | Genentech, Inc. | Treatment with anti-VEGF antibodies |
| US20050048578A1 (en) * | 2003-06-26 | 2005-03-03 | Epitomics, Inc. | Methods of screening for monoclonal antibodies with desirable activity |
| WO2005044853A2 (en) * | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| CN100415765C (zh) * | 2003-08-07 | 2008-09-03 | 宜康公司 | 兔单克隆抗体的人源化方法 |
| JP5014130B2 (ja) | 2004-08-02 | 2012-08-29 | ズィナイス オペレーションズ ピーティーワイ．エルティーディー． | Ｖｅｇｆ−ｂアンタゴニストを含む癌治療方法 |
| NZ596663A (en) | 2004-10-21 | 2013-07-26 | Genentech Inc | Use of vegf antagonists in intraocular neovascular disease treatment |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| AU2006281980A1 (en) * | 2005-08-15 | 2007-02-22 | Cephalon Australia Pty Ltd | Engineered antibodies with new world primate framework regions |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| WO2007140534A1 (en) * | 2006-06-08 | 2007-12-13 | Csl Limited | Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling |
| CN103251947B (zh) | 2006-07-10 | 2017-11-21 | 艾斯巴技术-诺华有限责任公司 | 穿过上皮和/或内皮层的scFV抗体 |
| AU2007323925A1 (en) | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
| US7553486B2 (en) | 2006-11-13 | 2009-06-30 | Paul Theodore Finger | Anti-VEGF treatment for radiation-induced vasculopathy |
| EP3095455A1 (en) | 2006-12-19 | 2016-11-23 | Genentech, Inc. | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| CN101668771B (zh) | 2007-03-12 | 2013-08-21 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 单链抗体的基于序列的工程改造和最优化 |
| WO2008149147A2 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| CA2688434A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| PL2164961T3 (pl) | 2007-06-25 | 2015-08-31 | Esbatech Alcon Biomed Res Unit | Oparta na sekwencjach inżynieria i optymalizacja przeciwciał jednołańcuchowych |
| PL2158315T3 (pl) | 2007-06-25 | 2016-10-31 | Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych | |
| US7803371B2 (en) * | 2008-03-26 | 2010-09-28 | Epitomics, Inc. | Anti-VEGF antibody |
| KR20180005753A (ko) * | 2008-06-25 | 2018-01-16 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체 |
| TR201808591T4 (tr) * | 2008-06-25 | 2018-07-23 | Esbatech Alcon Biomed Res Unit | Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması. |
| ES2884117T3 (es) | 2008-06-25 | 2021-12-10 | Novartis Ag | Optimización de la solubilidad de inmunoaglutinantes |
| CA2730178A1 (en) * | 2008-07-10 | 2010-01-14 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods and compositions for enhanced delivery of macromolecules |
| JP5914353B2 (ja) * | 2009-12-23 | 2016-05-11 | エスバテック − ア ノバルティス カンパニー エルエルシー | 免疫原性を減少させるための方法 |
-
2009
- 2009-06-25 KR KR1020187000324A patent/KR20180005753A/ko not_active Abandoned
- 2009-06-25 PL PL17151756T patent/PL3216803T3/pl unknown
- 2009-06-25 DK DK17151756.8T patent/DK3216803T3/da active
- 2009-06-25 SI SI200931647A patent/SI2307454T1/sl unknown
- 2009-06-25 JP JP2011515049A patent/JP5956752B2/ja active Active
- 2009-06-25 MX MX2017006583A patent/MX392435B/es unknown
- 2009-06-25 KR KR1020207026266A patent/KR102296443B1/ko active Active
- 2009-06-25 KR KR1020187024733A patent/KR102095257B1/ko active Active
- 2009-06-25 DK DK20158159.2T patent/DK3722310T3/da active
- 2009-06-25 KR KR1020117001961A patent/KR102013220B1/ko active Active
- 2009-06-25 RU RU2011102583A patent/RU2531523C3/ru active
- 2009-06-25 LT LTEP17151756.8T patent/LT3216803T/lt unknown
- 2009-06-25 AU AU2009264565A patent/AU2009264565C1/en active Active
- 2009-06-25 LT LTEP09768693.5T patent/LT2307454T/lt unknown
- 2009-06-25 MX MX2011000011A patent/MX2011000011A/es active IP Right Grant
- 2009-06-25 LT LTEP20158159.2T patent/LT3722310T/lt unknown
- 2009-06-25 PT PT201581592T patent/PT3722310T/pt unknown
- 2009-06-25 MX MX2013004871A patent/MX347972B/es unknown
- 2009-06-25 HU HUE20158159A patent/HUE068894T2/hu unknown
- 2009-06-25 ES ES17151756T patent/ES2793008T3/es active Active
- 2009-06-25 PT PT97686935T patent/PT2307454T/pt unknown
- 2009-06-25 HR HRP20241467TT patent/HRP20241467T1/hr unknown
- 2009-06-25 SI SI200932061T patent/SI3216803T1/sl unknown
- 2009-06-25 BR BRPI0914251-7A patent/BRPI0914251B1/pt active IP Right Grant
- 2009-06-25 SI SI200932208T patent/SI3722310T1/sl unknown
- 2009-06-25 PL PL20158159.2T patent/PL3722310T3/pl unknown
- 2009-06-25 FI FIEP20158159.2T patent/FI3722310T3/fi active
- 2009-06-25 CN CN201510205513.0A patent/CN104961828B/zh active Active
- 2009-06-25 ES ES09768693.5T patent/ES2622470T3/es active Active
- 2009-06-25 CA CA2727839A patent/CA2727839C/en active Active
- 2009-06-25 HU HUE09768693A patent/HUE032894T2/hu unknown
- 2009-06-25 KR KR1020167030125A patent/KR101737466B1/ko active Active
- 2009-06-25 EP EP17151756.8A patent/EP3216803B1/en active Active
- 2009-06-25 EP EP20158159.2A patent/EP3722310B1/en active Active
- 2009-06-25 ES ES20158159T patent/ES2998307T3/es active Active
- 2009-06-25 KR KR1020157032314A patent/KR101671886B1/ko active Active
- 2009-06-25 DK DK09768693.5T patent/DK2307454T3/en active
- 2009-06-25 WO PCT/CH2009/000220 patent/WO2009155724A2/en not_active Ceased
- 2009-06-25 US US13/000,423 patent/US8349322B2/en active Active
- 2009-06-25 PL PL09768693T patent/PL2307454T3/pl unknown
- 2009-06-25 KR KR1020197022648A patent/KR102157097B1/ko active Active
- 2009-06-25 EP EP09768693.5A patent/EP2307454B1/en active Active
- 2009-06-25 PT PT171517568T patent/PT3216803T/pt unknown
- 2009-06-25 KR KR1020177012884A patent/KR101817284B1/ko active Active
- 2009-06-25 CN CN200980124313.5A patent/CN102143976B/zh active Active
- 2009-06-25 CA CA3020290A patent/CA3020290A1/en active Pending
- 2009-06-25 CN CN201910338494.7A patent/CN110372792A/zh active Pending
- 2009-06-25 RU RU2014132888A patent/RU2588467C3/ru active Protection Beyond IP Right Term
- 2009-06-25 HR HRP20170615TT patent/HRP20170615T1/hr unknown
- 2009-06-25 HU HUE17151756A patent/HUE050230T2/hu unknown
-
2010
- 2010-11-30 ZA ZA2010/08594A patent/ZA201008594B/en unknown
- 2010-12-23 CL CL2010001544A patent/CL2010001544A1/es unknown
-
2012
- 2012-12-07 US US13/708,575 patent/US9090684B2/en active Active
-
2013
- 2013-07-19 RU RU2013133802/10A patent/RU2013133802A/ru not_active Application Discontinuation
-
2014
- 2014-04-21 JP JP2014087194A patent/JP6100199B2/ja active Active
-
2015
- 2015-02-27 JP JP2015037794A patent/JP2015134792A/ja active Pending
- 2015-06-16 US US14/741,430 patent/US9873737B2/en active Active
- 2015-07-20 PH PH12015501593A patent/PH12015501593A1/en unknown
-
2016
- 2016-05-18 RU RU2016119152A patent/RU2648152C2/ru active
- 2016-12-28 JP JP2016255720A patent/JP6527128B2/ja active Active
-
2017
- 2017-04-12 CY CY20171100436T patent/CY1118829T1/el unknown
- 2017-11-16 US US15/814,784 patent/US10590193B2/en active Active
-
2018
- 2018-02-05 JP JP2018018375A patent/JP6821612B2/ja active Active
- 2018-02-16 RU RU2018105866A patent/RU2696972C1/ru active
-
2019
- 2019-05-13 JP JP2019090735A patent/JP6978468B2/ja active Active
- 2019-06-27 RU RU2019120079A patent/RU2747735C3/ru active
-
2020
- 2020-01-31 US US16/779,028 patent/US20200172608A1/en not_active Abandoned
- 2020-05-19 HR HRP20200814TT patent/HRP20200814T1/hr unknown
- 2020-06-05 CY CY20201100507T patent/CY1123028T1/el unknown
- 2020-07-23 LT LTPA2020004C patent/LTC2307454I2/lt unknown
- 2020-07-27 HU HUS2000028C patent/HUS2000028I1/hu unknown
- 2020-07-28 NL NL301058C patent/NL301058I2/nl unknown
- 2020-07-30 CY CY2020026C patent/CY2020026I1/el unknown
- 2020-08-04 NO NO2020021C patent/NO2020021I1/no unknown
-
2021
- 2021-11-11 JP JP2021184262A patent/JP7171877B6/ja active Active
-
2023
- 2023-02-07 US US18/165,845 patent/US20250066462A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014132888A (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| IL302078A (en) | Anti-ccr8 monoclonal antibodies and uses thereof | |
| IL261585A (en) | Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes | |
| JP2018108081A5 (ru) | ||
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| RU2017104815A (ru) | Молекулы со специфичностью в отношении cd79 и cd22 | |
| RU2010141584A (ru) | Антитело против csf-1r | |
| JP2013510868A5 (ru) | ||
| JP2020514310A5 (ru) | ||
| HRP20230078T1 (hr) | Sredstva za vezivanje vegf/dll4 i njihova uporaba | |
| RU2013152164A (ru) | Анти-в7-н3-антитело | |
| RU2006137060A (ru) | Человеческие антитела к рецептору эпидермального фактора роста | |
| RU2013124808A (ru) | Новое антитело против dr5 | |
| HRP20170524T1 (hr) | Humana protutijela koja vežu humani protein 4 nalik angiopoietinu | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| RU2017104813A (ru) | Молекулы со специфичностью к cd45 и cd79 | |
| JP2009539403A5 (ru) | ||
| JP2020502271A5 (ru) | ||
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| RU2018126318A (ru) | Молекулы полиспецифичных антител, имеющие специфичность к tnf-альфа, il-17a и il-17f | |
| JP2025092589A5 (ru) | ||
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| RU2016136527A (ru) | Улучшенные способы лечения васкуляризированных злокачественных опухолей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20200310 |
|
| ND4A | Extension of patent duration |
Effective date: 20211020 |